Nightstar Therapeutics (NITE) PT Raised to $36 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Nightstar Therapeutics (NITE) PT Raised to $36 at Wedbush
September 22, 2018 11:58 AM EDT
NSR-RPGR data presented at EURETINA 2018 Congress demonstrated proof of concept with durable dose-related improvements seen as early as month 1 across multiple microperimetry analyses
Preliminary efficacy signals observed in 3/3 patients in cohort 3 and 2/6 patients in cohorts 4 and 5, including durable improvements in overall macula sensitivity, central 16 macula sensitivity and number of improved macula loci
NSR-RPGR was well-tolerated with no dose limiting toxicities or serious treatment-related adverse events
XIRIUS expansion study planned to initiate in Q4 2018
Detailed results to be presented at R&D day... More
September 22, 2018 11:57 AM EDT
NSR-RPGR data presented at EURETINA 2018 Congress demonstrated proof of concept with durable dose-related improvements seen as early as month 1 across multiple microperimetry analyses
Preliminary efficacy signals observed in 3/3 patients in cohort 3 and 2/6 patients in cohorts 4 and 5, including durable improvements in overall macula sensitivity, central 16 macula sensitivity and number of improved macula loci
NSR-RPGR was well-tolerated with no dose limiting toxicities or serious treatment-related adverse events
XIRIUS expansion study planned to initiate in Q4 2018
Detailed results to be presented at R&D day on... More
